IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV

Cabotegravir + rilpivirine (CAB+RPV) long-acting (LA) antiretroviral therapy (ART) consistently maintains virologic suppression among virologically suppressed adults with HIV, according to a study presented at the annual meeting of the Infectious Diseases Society of America (IDWeek), held from Oct. 21 to 24 in Washington, D.C.

Read it at Medical Xpress ↗

← Front page